Literature DB >> 21953306

Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: two subsets of giant cell arteritis.

Giovanna Restuccia1, Alberto Cavazza, Luigi Boiardi, Nicolò Pipitone, PierLuigi Macchioni, GianLuigi Bajocchi, Maria Grazia Catanoso, Francesco Muratore, Alessandra Ghinoi, Luca Magnani, Luca Cimino, Carlo Salvarani.   

Abstract

OBJECTIVE: To evaluate the frequency and clinical characteristics of periadventitial small-vessel vasculitis (SVV) and isolated vasa vasorum vasculitis (VVV).
METHODS: We identified 455 temporal artery biopsies performed in residents of Reggio Emilia, Italy between 1986 and 2003. Slides of temporal artery biopsy specimens were reviewed by a pathologist who was blinded with regard to clinical data. SVV was defined as inflammation of the small vessels external to the temporal artery adventitia, and VVV was defined as isolated inflammation of temporal artery vasa vasorum. Medical records of patients with SVV and/or VVV were reviewed, and demographic, clinical, laboratory, and followup data were collected. For comparison purposes, we collected the same data from an equal number of randomly selected patients with evidence of classic giant cell arteritis (GCA).
RESULTS: Sixteen patients had SVV, 18 had isolated VVV, and 5 had both SVV and VVV. Compared with patients with classic GCA, the frequencies of headache, scalp tenderness, abnormalities of temporal arteries, jaw claudication, anorexia, and weight loss, the levels of acute-phase reactant at diagnosis, and the initial and cumulative doses prednisone were significantly lower and the frequency of peripheral synovitis was higher in the patients with SVV, and the frequency of cranial ischemic events was similar in the 2 groups. In contrast, the clinical characteristics and erythrocyte sedimentation rate at diagnosis of patients with isolated VVV were similar to those of patients with classic GCA.
CONCLUSION: Our findings indicate that isolated VVV and SVV should be considered part of the histopathologic spectrum of GCA.
Copyright © 2012 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2012        PMID: 21953306     DOI: 10.1002/art.33362

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis.

Authors:  Lindsay Lally; Alessandra Pernis; Navneet Narula; Wei-Ti Huang; Robert Spiera
Journal:  Rheumatology (Oxford)       Date:  2014-09-10       Impact factor: 7.580

Review 2.  Clinical features of polymyalgia rheumatica and giant cell arteritis.

Authors:  Carlo Salvarani; Nicolò Pipitone; Annibale Versari; Gene G Hunder
Journal:  Nat Rev Rheumatol       Date:  2012-07-24       Impact factor: 20.543

Review 3.  Interleukin-9 and T helper type 9 cells in rheumatic diseases.

Authors:  F Ciccia; G Guggino; A Ferrante; P Cipriani; R Giacomelli; G Triolo
Journal:  Clin Exp Immunol       Date:  2016-08       Impact factor: 4.330

4.  Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients.

Authors:  Francesca Regola; Elisabetta Cerudelli; Giovanni Bosio; Laura Andreoli; Angela Tincani; Franco Franceschini; Paola Toniati
Journal:  Rheumatol Adv Pract       Date:  2020-05-15

5.  Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis.

Authors:  José Hernández-Rodríguez; Giuseppe Murgia; Irama Villar; Elías Campo; Sarah L Mackie; Aruna Chakrabarty; Elizabeth M A Hensor; Ann W Morgan; Carme Font; Sergio Prieto-González; Georgina Espígol-Frigolé; Josep M Grau; Maria C Cid
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 6.  Temporal Artery Vascular Diseases.

Authors:  Hélène Greigert; André Ramon; Georges Tarris; Laurent Martin; Bernard Bonnotte; Maxime Samson
Journal:  J Clin Med       Date:  2022-01-05       Impact factor: 4.241

7.  TLR-4 and VEGF polymorphisms in chronic periaortitis.

Authors:  Fabiola Atzeni; Luigi Boiardi; Augusto Vaglio; Davide Nicoli; Enrico Farnetti; Alessandra Palmisano; Nicolò Pipitone; Davide Martorana; Gabriella Moroni; Selena Longhi; Francesco Bonatti; Carlo Buzio; Carlo Salvarani
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

Review 8.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Authors:  Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Arthritis Rheumatol       Date:  2018-07-30       Impact factor: 10.995

9.  Clinical comparisons of patients with giant cell arteritis with versus without fever at onset.

Authors:  Yun Zhang; Dongmei Wang; Yue Yin; Hongwei Fan; Wen Zhang; Xuejun Zeng
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.